Dernières nouvelles pour Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.

News

Price Target

Reiteration

Analyst Ratings

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").
OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.

Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.

Biotech

Health Care

General

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."

Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.

Initiation

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024

NNVC

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) today announced it has agreed to acquire Lexmark International, Inc., from Ninestar Corporation, PAG Asia Capital, and Shanghai Shouda Investment Centre in a deal valued at $1.5 billion, inclusive of assumed liabilities. This acquisition will strengthen the Xerox core print portfolio and build a broader global print and managed print services business better suited to meet the evolving needs of clients in the hybrid workplace.

Xerox to Acquire Lexmark in $1.5B Deal to Expand Print Services

On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities").
On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities"). The purchase price for the Facilities is $24,000,000, payable at the closing.
The six facilities are comprised of five skilled nursing facilities and one assisted living facility with 354 licensed beds.
The facilities will be leased to Advena Living led by its founder Willie Novotny. The lease is for an initial 10-year period and includes two 5-year tenant options on a triple-net basis. Additionally, the lease will increase the Company's annual rents by $2.4 million and is subject to 3% annual increases.
The Company plans to purchase the facilities utilizing the Company's current working capital.

STRW

Strawberry Fields REIT To Acquire Six Kansas Healthcare Facilities for $24M

Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
"It is estimated that 1 in 10 dogs will experience heart disease in their life and unfortunately, most go undetected," said Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica. "Diagnosing and evaluating cardiac disease in our canine patients can be challenging. The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes. This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients' quality of life earlier in the disease process." Additionally, this assay runs on either plasma or serum allowing more flexibility within a clinic's natural workflow.
 &nbsp;

Zomedica Launches New Canine Tests for Faster Heart Disease Detection

HC Wainwright &amp; Co. analyst Scott Buck maintains SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and raises the price target from $8 to $26.

SOUN

HC Wainwright & Co. Maintains Buy on SoundHound AI, Raises Price Target to $26

<a href="https://www.globenewswire.com/Tracker?data=EvK5qYIL7c_16K93ZBIV_UFtMgPcLGgkcD7IshY3PCtSMlupDBlYnqtVSWF1N4Gw2XKatFqrvbqOxjYWR9wI5K4prfcV9UU3A5dR9pU3RKI=">Hyperscale Data, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("Hyperscale Data" or the "Company"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") providing for up to $25 million of financing (the "Financing") from Ault &amp; Company, Inc., a related party ("A&amp;C"). Pursuant to the Agreement, Hyperscale Data has agreed to issue and sell to A&amp;C up to $25 million in shares of Series G Convertible Preferred Stock (the "Preferred Shares"). The Preferred Shares will be senior to all other classes of preferred stock the Company has outstanding except with respect to the Series C Convertible Preferred Stock (the "Series C Preferred Stock"), with which it ranks in parity, as well as senior to the Company's Class A common stock ("Common Stock").
Each Preferred Share shall have a stated value of $1,000.00 per share and, upon stockholder approval, shall be convertible at the holder's option into shares of Common Stock at a conversion price equal to the greater of (i) $0.10 per share (the "Floor Price"), which Floor Price shall not, except for voting rights purposes, be adjusted for stock dividends, stock splits, stock combinations and other similar transactions and (ii) the lesser of (A) $6.74, or (B) a 5% premium to the closing sale price of the Common stock on the day immediately prior to the date of conversion (the "Conversion Price"). The Conversion Price will be subject to standard anti-dilution provisions in connection with any stock split, stock dividend, subdivision or similar reclassification of the Common Stock. The Preferred Stock also has "full ratchet" price protection in the event the Company should issue securities at a lower price than the Conversion Price. The Preferred Stock shall pay a dividend at an annual rate of 9.5%, which the Company may, during the first two years, pay in shares of Common Stock.
Further, A&amp;C will receive warrants ("Warrants") to purchase up to approximately 4.25 million shares of Common Stock, presuming that the full amount of the Preferred Shares is sold, exercisable for five years at $5.92 per share, subject to adjustment.
The proceeds from the Financing will be used for expansion of the MI data center to support infrastructure upgrades necessary to support the growing demands of high-performance computing services powering Artificial Intelligence solutions, repayment of outstanding indebtedness and general working capital purposes.

Hyperscale Data Secures $25M Financing to Boost AI Infrastructure Expansion

HC Wainwright &amp; Co. analyst Scott Buck maintains Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) with a Buy and raises the price target from $5 to $7.

DPRO

HC Wainwright & Co. Maintains Buy on Draganfly, Raises Price Target to $7

Elanco Animal Health ( ($ELAN) ) has provided an update. Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, enhancing its ...

Elanco Animal Health Strengthens Board with New Appointment

In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Elanco Animal Health (ELAN – Research Report), with a price t...

Jefferies Keeps Their Buy Rating on Elanco Animal Health (ELAN)

Elanco (ELAN) Animal Health acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Spe...

Elanco acquires contract manufacturing facility in Speke, UK

Elanco buys key U.K. manufacturing site for $25M

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Oppenheimer's top Buy and Sell ideas from each of the sectors

A class action lawsuit was filed against Elanco Animal Health Inc. ($ELAN) by Levi & Korsinsky on October 7, 2024. The plaintiffs (shareholders) al...

Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)

Zoetis: Healing Paws, Growing Profits

Leerink analyst Daniel Clark initiated coverage of Elanco (ELAN) with a Market Perform rating and $14 price target The firm notes Elanco trades at ...

Elanco initiated with a Market Perform at Leerink

UBS initiated coverage of Elanco (ELAN) with a Buy rating and $18 price target The shares are down 19% year-to-date and 7% last week alone on Zenre...

Elanco initiated with a Buy at UBS

ANDE

BIIB

BNTX

CARS

CWEN

CYBR

ELAN

HWKN

IDXX

LMAT

LSCC

MRNA

MSGS

NAVI

PGNY

VRTX

Press Releases

ELAN Deadline: ELAN Investors Have Opportunity to Lead Elanco Animal Health Incorporated Lawsuit

Class Action Filed Against Elanco Animal Health Incorporated (ELAN) - December 6, 2024 Deadline to Join - Contact Levi & Korsinsky

Legal

ELAN CLASS ACTION DEADLINE IS TODAY: Elanco Investors are Alerted of December 6 Deadline in Securities Fraud Class Action – Contact BFA Law Now (NYSE:ELAN)

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health

ELAN Deadline Today: Rosen Law Firm Urges Elanco Animal Health Incorporated (NYSE: ELAN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco Animal Health Incorporated shares should contact the Shareholders Foundation

Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Elanco Animal Health Incorporated of Class Action Lawsuit and Upcoming Deadlines – ELAN

Elanco to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Elanco Animal Health

Actualités

Dernières nouvelles pour Elanco Animal Health (NYSE:ELAN) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL